Drug
ESL 800 mg
ESL 800 mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Anti-epileptogenic Effects of Eslicarbazepine Acetate
NCT06597084
completedphase_3
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
NCT02484001
completedphase_2
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
NCT01820585
completedphase_2
Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine
NCT01820559
Clinical Trials (4)
Showing 4 of 4 trials
NCT06597084Phase 2
Anti-epileptogenic Effects of Eslicarbazepine Acetate
NCT02484001Phase 3
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
NCT01820585Phase 2
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
NCT01820559Phase 2
Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4